Eli Lilly's dual agonist tirzepatide has no obvious advantage over competitor drugs!

Compilenewborn

So far, the clinical data for Eli Lilly and Co.

This is the central question of a recent Institute for Clinical and Economic Review (ICER) report on Lilly's highly promising dual-target GLP-R/GIPR agonist, tirzepatide

Tirzepatide is a novel, once-weekly dual agonist of glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor

Currently, tirzepatide is being developed to treat type 2 diabetes and obesity

In the published assessment report, ICER noted that the available data on tirzepatide "highly affirmatively" suggest that adding tirzepatide to background therapy "has at least a small and potentially substantial net health benefit"

In a head-to-head clinical trial of Ozempic, tirzepatide demonstrated greater reductions in blood sugar levels, body weight, triglycerides and blood pressure, Dr.

Based on current data, ICER believes a reasonable price for tirzepatide could be between $5,500 and $5,700 a year

Meanwhile, ICER points out that, in terms of heart health, the results of the tirzepatide trial are yet to come

Beyond diabetes, tirzepatide could eventually also compete with Novo Nordisk's Wegovy in obesity

Source: Lilly's tirzepatide doesn't necessarily top diabetes rivals Jardiance and Ozempic, ICER says